Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of VSA001 injection in Chinese adults with familial chylomicronemia syndrome
CTR20231418Phase 3Completed
- Sponsor
- Visirna Therapeutics
- Start
- Jul 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of plozasiran in primary chylomicronemia (FCS), sponsored by Visirna Therapeutics. Started Jul 2023; status: completed.
02
Drugs
plozasiran
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on CTR20231418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231418.